Kopran Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Kopran Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $7.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kopran Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $7.3M Trade | TransData Nexus

Kopran Limited

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $7.3M Total Trade · DGFT Verified

Kopran Limited is an Indian pharmaceutical exporter with a total trade value of $7.3M across 6 products in 5 therapeutic categories. Based on 276 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Kit ($2.6M), Enalapril ($1.5M), Flucloxacillin ($1.3M).

Kopran Limited — Export Portfolio & Destination Treemap

Kopran Limited pharmaceutical export portfolio — 6 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Kopran Limited? — Company Overview & Market Position

Kopran Limited, established on April 26, 1958, is an integrated pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company specializes in the development, manufacture, and marketing of both active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, syrups, and injectables. Kopran's diverse product portfolio encompasses a wide range of therapeutic categories, such as macrolides, antibacterials, anticonvulsants, antihypertensives, and anti-infectives.

As of March 12, 2026, Kopran Limited's stock is listed on the National Stock Exchange of India under the ticker symbol KOPRAN, with a closing price of ₹122.01. The company reported a revenue of ₹63,359 lakhs for the fiscal year 2024-25, with an EBITDA of ₹7,290 lakhs and a profit after tax of ₹3,855 lakhs. Kopran employs a team of over 800 professionals, reflecting its commitment to quality and innovation in the pharmaceutical industry.

What Does Kopran Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Kit$2.6M 2

Product Portfolio — Top 6 by Export Value

Kopran Limited exports 6 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Kit	Medical Devices & Diagnostics	$2.6M	124	0.6%	14
2	Enalapril	Cardiovascular	$1.5M	66	0.6%	6
3	Flucloxacillin	Advanced Antibiotics	$1.3M	26	3.4%	6
4	Clarithromycin	Antibiotics	$888.1K	21	0.9%	14
5	Atenolol	Cardiovascular	$553.2K	30	1.4%	15
6	Salmeterol	Respiratory	$392.3K	9	0.5%	11

Kopran Limited exports 6 pharmaceutical products across 5 therapeutic categories with a total export value of $7.3M. The top category is Medical Devices & Diagnostics (35.9% of portfolio), followed by Cardiovascular (28.5%), indicating a concentrated portfolio with the top 5 products accounting for 94.6% of total export value.

Kopran Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Kopran Limited operates state-of-the-art manufacturing facilities in India, strategically located to support its diverse product range. The company's API manufacturing plant is situated in Mahad, Maharashtra, while its finished dosage forms are produced at the Khopoli facility, also in Maharashtra. These facilities are equipped with advanced technology and adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at Kopran Limited is headed by Executive Vice Chairman Mr. Surendra Somani, who has been with the company since 1981 and brings extensive experience in the pharmaceutical industry. Other key executives include Mr. Basant Kumar Soni, the Chief Financial Officer, and Mr. Ajit Jain, the Chief Operating Officer. The Board of Directors comprises individuals with diverse expertise, including independent directors such as Mrs. Mamta Biyani and Mr. Narayan Atal, who contribute to the company's strategic direction and governance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Kopran Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Kopran Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from various regulatory bodies, such as the EU GMP, MHRA (UK), and Health Canada, facilitating market access in these regions. Additionally, Kopran's products are approved by the FDA in the United States and the TGA in Australia, demonstrating compliance with international quality standards.

2Emerging Markets

Kopran Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 60 countries, including regions such as South Africa, Mexico, China, and the United Kingdom. This global reach is supported by the company's WHO GMP certification, which enhances its ability to meet the quality standards required for market entry in these regions.

3Geographic Strategy

Kopran Limited's geographic strategy demonstrates a balanced approach to market diversification. While the company has a strong presence in regulated markets, it has also made significant inroads into emerging markets, mitigating concentration risk. This strategic diversification allows Kopran to leverage growth opportunities across different regions, aligning with its mission to provide affordable medicines globally.

Kopran Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Kopran Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has received approvals for its Abbreviated New Drug Applications (ANDAs), allowing it to market generic formulations in the U.S. market. Additionally, Kopran has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes of its APIs. The company's facilities have undergone FDA inspections, reflecting its commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

Kopran Limited's manufacturing facilities hold certifications from the World Health Organization's Good Manufacturing Practices (WHO GMP) and the European Union's Good Manufacturing Practices (EU GMP). These certifications affirm the company's adherence to international quality standards, facilitating access to global markets and reinforcing its reputation for quality and reliability.

3CDSCO & Indian Regulatory

Kopran Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Kopran Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the generic formulations segment, it competes with companies like Cipla, Dr. Reddy's Laboratories, and Lupin Pharmaceuticals. In the API manufacturing sector, competitors include Aurobindo Pharma and Sun Pharmaceutical Industries. Kopran's focus on quality, regulatory compliance, and a diverse product portfolio positions it favorably in the market.

2Key Differentiators

Kopran Limited's key differentiators include its extensive experience of over 60 years in the pharmaceutical industry, a diverse product portfolio covering multiple therapeutic categories, and manufacturing facilities accredited by international regulatory bodies. The company's commitment to research and development, along with its focus on quality and affordability, further distinguishes it in the global pharmaceutical market.

3Strategic Position

Kopran Limited's current strategic direction emphasizes the development and manufacturing of both generic formulations and APIs, with a focus on expanding its presence in regulated and emerging markets. The company's future outlook includes leveraging its R&D capabilities to introduce new products, enhancing its manufacturing processes, and strengthening its global distribution network to meet the growing demand for affordable and high-quality pharmaceutical products.

Buyer Due Diligence Brief — Evaluating Kopran Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Kopran Limited has a strong track record in the pharmaceutical industry, with a consistent export volume of $7.3 million USD across 276 shipments from 2022 to 2026. The company's portfolio concentration, with the top five products accounting for 94.6% of exports, indicates a focused approach to its product offerings. Kopran's adherence to international quality standards and regulatory compliance further enhances its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Kopran Limited as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulatory standards.

WHO GMP Certification: Verify the World Health Organization's Good Manufacturing Practices certification to ensure adherence to international quality standards.

Frequently Asked Questions — Kopran Limited

How many pharmaceutical products does Kopran Limited export from India?

Kopran Limited exports 6 pharmaceutical products across 5 therapeutic categories. The top exports are Kit ($2.6M), Enalapril ($1.5M), Flucloxacillin ($1.3M), Clarithromycin ($888.1K), Atenolol ($553.2K). Total export value is $7.3M.

What is Kopran Limited's total pharmaceutical export value?

Kopran Limited's total pharmaceutical export value is $7.3M, based on 276 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Kopran Limited cover?

Kopran Limited exports across 5 therapeutic categories. The largest are Medical Devices & Diagnostics (35.9%, 1 products), Cardiovascular (28.5%, 2 products), Advanced Antibiotics (17.9%, 1 products).

Get Full Kopran Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.